ASCO: AstraZeneca's Enhertu Is Poised To Change The Breast Cancer Paradigm

The results of DESTINY-Breast04 could impact survival for approximately 50% of patients diagnosed with metastatic breast cancer today, principal investigator Modi said at the American Society of Clinical Oncology annual meeting.